Welcome to our dedicated page for Neurobo Pharmaceuticals news (Ticker: NRBO), a resource for investors and traders seeking the latest updates and insights on Neurobo Pharmaceuticals stock.
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), now operating under the name MetaVia Inc., generates a steady stream of news as a clinical-stage biotechnology company focused on cardiometabolic diseases. Company announcements highlight progress with its two primary investigational drugs: DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH).
News items commonly cover clinical trial milestones, such as completion of enrollment, last patient last visit, and top-line data readouts from the Phase 1 program of DA-1726 and the Phase 2a program of DA-1241. Releases also describe the design of these studies, including single and multiple ascending dose components for DA-1726 and the two-part, randomized, double-blind, placebo-controlled structure of the DA-1241 MASH trial.
Investors following NRBO-related news can also expect corporate updates, including the strategic realignment around cardiometabolic assets, the announced corporate name change to MetaVia Inc. with an expected Nasdaq ticker change to MTVA, and financing transactions that support the advancement of DA-1726 and DA-1241. Financial results releases provide context on research and development spending, general and administrative expenses, and cash runway in relation to planned clinical milestones.
Additional news coverage includes participation in investor and scientific conferences, joint research agreements related to DA-1726 and DA-1241, and collaborations described in SEC filings. For users tracking NRBO, this news feed offers a consolidated view of historical and transitional developments as the company continues its cardiometabolic drug development under the MetaVia identity.
SMX (NASDAQ:SMX) argues supply‑chain integrity must shift from declared compliance to engineered, verifiable certainty by embedding molecular‑level identity into materials so proof travels with the asset.
The company emphasizes long timelines, disciplined deployments, and non‑disruptive capital to ensure systems validate under real conditions and survive regulatory scrutiny. SMX positions its technology and capital strategy as complementary: material verification paired with corporate stability to support national and industrial integrations where continuity is essential.
The release frames regulation as a filter that favors verification‑based systems, asserting SMX already operates within that proof‑based future.
NeuroBo Pharmaceuticals announced a strategic realignment with a corporate name change to MetaVia Inc., effective November 29, 2024. The company's stock will trade under the new Nasdaq ticker symbol MTVA. This change reflects their focus on developing therapies for cardiometabolic diseases. The company remains well-funded following a June financing of up to $70 million. Key upcoming milestones include Phase 2a trial data for DA-1241 (MASH treatment) in December 2024 and Phase 1 MAD trial results for DA-1726 (obesity treatment) in Q1 2025.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotechnology company focused on cardiometabolic diseases, announces participation in two investor conferences this November. Hyung Heon Kim, President and CEO, and Marshall H. Woodworth, CFO, will present company overviews at the Life Science Virtual Investor Forum on November 14 at 1:00 pm ET and the Winter 2024 Investor Summit Virtual on November 21 at 11:00 am ET. Management will be available for one-on-one meetings during both events. Interested parties can register through provided links or contact Michael Miller for meetings outside these events.
NeuroBo Pharmaceuticals reported Q3 2024 financial results and clinical progress. The company announced positive top-line data from the SAD Part 1 Phase 1 trial of DA-1726 for obesity treatment, showing favorable safety and dose-linear pharmacokinetics. With $21.7 million cash on hand, operations are funded into Q3 2025. Key upcoming milestones include top-line results from DA-1241's Phase 2a MASH trial in December 2024 and DA-1726's MAD Part 2 data in Q1 2025. Q3 net loss was $5.7 million, with R&D expenses increasing to $4.5 million compared to $2.3 million in Q3 2023.
NeuroBo Pharmaceuticals has completed the last patient visit in its Phase 2a clinical trial of DA-1241, a GPR119 agonist for treating metabolic dysfunction-associated steatohepatitis (MASH). The trial consists of two parts: Part 1 comparing DA-1241 to placebo, and Part 2 testing DA-1241 combined with sitagliptin. Of 109 randomized patients, 95 completed the 16-week dosing period. The study's primary endpoint is measuring change in ALT levels at Week 16, with topline data expected in December 2024. The drug showed good tolerability in previous Phase 1 studies with healthy volunteers and type 2 diabetes patients.
NeuroBo Pharmaceuticals, a clinical-stage biotechnology company focused on cardiometabolic diseases, announced its participation in two investor conferences in October 2024:
1. H.C. Wainwright 8th Annual MASH Virtual Conference on October 7: President and CEO Hyung Heon Kim will present a company overview at 11:00 am ET. Management will be available for one-on-one meetings.
2. 2024 Maxim Healthcare Virtual Summit from October 15-17: Kim and CFO Marshall H. Woodworth will participate in a virtual fireside chat on October 15 at 2:30 pm ET.
Investors can register for the H.C. Wainwright conference at https://hcwevents.com/mashconference/. To schedule meetings outside these conferences, contact Michael Miller at mmiller@rxir.com.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) announced positive top-line data from Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study revealed favorable safety, tolerability, and dose-linear pharmacokinetics in 45 obese participants. Key findings include:
- No serious adverse events reported
- Only 5 subjects in the DA-1726 group reported adverse events vs. 3 in placebo
- Dose-linear PK profile observed across investigated dose range
- Additional cohorts being added to explore maximum tolerated dose
The company has initiated the multiple ascending dose (MAD) Part 2 study and expects top-line data in Q1 2025. A planned Part 3 will evaluate early proof of concept. NeuroBo believes DA-1726 could become a best-in-class obesity drug with better tolerability than current GLP-1 agonists.
NeuroBo Pharmaceuticals (Nasdaq: NRBO), a clinical-stage biotech company focusing on cardiometabolic diseases, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference. The event is scheduled for September 9-11, 2024, in New York.
Key points:
- President and CEO Hyung Heon Kim and CFO Marshall H. Woodworth will present a company overview on September 10 at 1:30 pm ET.
- Management will be available for one-on-one meetings during the conference.
- Institutional investors can register at www.hcwevents.com/annualconference to access the presentation or request meetings.
- For meetings outside the conference, investors can contact Michael Miller at mmiller@rxir.com.
NeuroBo Pharmaceuticals (NRBO) reported Q2 2024 financial results and provided a corporate update. Key highlights include:
- Completed a $70 million financing, with $20 million upfront and $50 million in milestone-based warrants
- $27.9 million cash at quarter-end, expected to fund operations into Q2 2025
- Fully enrolled SAD Part 1 of DA-1726 Phase 1 trial for obesity, with top-line data expected in Q3 2024
- Entered joint research agreement to develop long-acting formulation of DA-1726
- Part 2 of DA-1241 Phase 2a trial for MASH underway, top-line data expected in Q4 2024
- Net loss of $10.1 million for Q2 2024, compared to $0.7 million in Q2 2023
The company is advancing its cardiometabolic pipeline with multiple upcoming milestones for DA-1726 and DA-1241.
NeuroBo Pharmaceuticals (Nasdaq: NRBO) has completed enrollment for Part 1 of its Phase 1 clinical trial evaluating DA-1726, a novel dual oxyntomodulin analog agonist for obesity treatment. The single ascending dose (SAD) study enrolled 45 participants across 5 cohorts. No significant issues were encountered, allowing an accelerated start to the multiple ascending dose (MAD) Part 2.
Key points:
- Top-line data from SAD Part 1 expected in Q3 2024
- MAD Part 2 results anticipated in Q1 2025
- Pre-clinical data showed superior weight loss compared to semaglutide and tirzepatide
- DA-1726 may become a best-in-class obesity drug with better tolerability
- Part 3 of the trial planned to start in Q3 2025, with interim data expected mid-2026 and top-line results in H2 2026